AllianceBernstein’s Tempest Therapeutics TPST Stock Holding History

AllianceBernstein’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16	Closed	-$90K	–	3179
2017 Q1	$90K	Sell	16 -1	-6%	-$4.66K	﹤0.01%	2946
2016 Q4	$77K	Hold	17	–	–	﹤0.01%	2982
2016 Q3	$362K	Sell	17 -2	-11%	-$36.2K	﹤0.01%	2645
2016 Q2	$289K	Buy	19 +6	+46%	+$137K	﹤0.01%	2691
2016 Q1	$366K	Sell	13 -2	-13%	-$42.3K	﹤0.01%	2515
2015 Q4	$431K	Hold	15	–	–	﹤0.01%	2505
2015 Q3	$374K	Hold	15	–	–	﹤0.01%	2594
2015 Q2	$1.28M	Buy	15 +8	+114%	+$733K	﹤0.01%	2132
2015 Q1	$708K	Buy	7 +3	+75%	+$399K	﹤0.01%	2352
2014 Q4	$500K	Buy	+4	New	+$293K	﹤0.01%	2512
2014 Q3	–	Hold	0	–	–	–	3267
2014 Q2	–	Hold	0	–	–	–	3286
2014 Q1	–	Hold	0	–	–	–	3453
2013 Q4	–	Hold	0	–	–	–	3192
2013 Q3	–	Hold	0	–	–	–	3194
2013 Q2	–	Hold	0	–	–	–	3143

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's TPST Position: Q2 2017 in Review

AllianceBernstein sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 16 shares — an estimated $90K sold.

AllianceBernstein first reported a position in TPST in Q4 2014 and held it in 10 quarters. The position peaked at $1.28M in Q2 2015. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

AllianceBernstein reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
AllianceBernstein sold 16 Tempest Therapeutics shares in Q2 2017, an estimated $90K.
AllianceBernstein first reported a position in Tempest Therapeutics in Q4 2014 and held it in 10 quarters.
AllianceBernstein's Tempest Therapeutics position peaked at $1.28M in Q2 2015.
54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on AllianceBernstein's 13F filing for Q2 2017, filed 10 Aug 2017.